Athenex (ATNXQ) 10-Q 14 Aug 17 2017 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2017	Aug. 09, 2017
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q2
Trading Symbol	ATNX
Entity Registrant Name	ATHENEX, INC.
Entity Central Index Key	1,300,699
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		57,063,609

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (unaudited) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 55,150	$ 33,125
Short-term investments	30,150	8,628
Accounts receivable, net of chargebacks, allowance for doubtful accounts, and other deductions of $1,860 and $155, respectively	3,783	2,777
Inventories, net	9,260	4,240
Prepaid expenses and other current assets	3,978	3,153
Total current assets	102,321	51,923
Property and equipment, net	8,321	5,810
Goodwill	37,600	37,552
Intangible assets, net	9,242	8,464
Other long-term assets	330	2,141
Total assets	157,814	105,890
Current liabilities:
Accounts payable	7,315	7,174
Accrued expenses	17,886	18,956
Current portion of long-term debt - related parties	1,064	1,123
Current portion of long-term debt	832	766
Total current liabilities	27,097	28,019
Long-term liabilities:
Deferred compensation	2,052	2,174
Deferred rent	1,328	904
Deferred income tax liability	98	206
Capital lease obligation	191
Long-term debt - related parties		496
Convertible bonds	5,042	14,498
Convertible bonds - related parties		16,129
Derivative liability	1,632	8,795
Total liabilities	37,440	71,221
Commitments and contingencies (Note 13)
Stockholders' equity:
Common stock, par value $0.001 per share, 250,000,000 shares authorized at June 30, 2017 and December 31, 2016; 58,736,529 and 42,342,706 shares issued at June 30, 2017 and December 31, 2016, respectively; 57,063,609 and 40,685,786 shares outstanding at June 30, 2017 and December 31, 2016, respectively	59	42
Additional paid-in capital	402,267	237,581
Accumulated other comprehensive loss	(658)	(1,304)
Accumulated deficit	(274,719)	(195,106)
Less: treasury stock, at cost; 1,672,920 and 1,656,920 shares at June 30, 2017 and December 31, 2016, respectively	(7,406)	(7,406)
Total Athenex, Inc. stockholders' equity	119,543	33,807
Non-controlling interests	831	862
Total stockholders' equity	120,374	34,669
Total liabilities and stockholders' equity	$ 157,814	$ 105,890

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) (unaudited) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Statement Of Financial Position [Abstract]
Accounts receivable, chargebacks, allowance for doubtful accounts, and other deductions (in dollars)	$ 1,860	$ 155
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	58,736,529	42,342,706
Common Stock, shares outstanding	57,063,609	40,685,786
Treasury stock, shares	1,672,920	1,656,920

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Revenue:
Product sales, net	$ 4,416	$ 4,820	$ 8,316	$ 9,308
License fees and consulting revenue	98	71	696	166
Grant revenue	81	302	164	348
Total revenue	4,595	5,193	9,176	9,822
Costs and operating expenses:
Cost of product sales	4,137	4,834	6,976	8,976
Research and development expenses	17,597	8,645	44,005	15,391
Selling, general, and administrative expenses	13,632	4,567	23,431	8,904
Total costs and operating expenses	35,366	18,046	74,412	33,271
Operating loss	(30,771)	(12,853)	(65,236)	(23,449)
Interest expense	3,281	49	5,657	3
Unrealized loss on derivative liability	4,587		8,863
Loss before income tax expense (benefit)	(38,639)	(12,902)	(79,756)	(23,452)
Income tax expense (benefit)	29	(403)	(63)	(303)
Net loss	(38,668)	(12,499)	(79,693)	(23,149)
Less: net loss attributable to non-controlling interests	(43)	(78)	(80)	(110)
Net loss attributable to Athenex, Inc.	(38,625)	(12,421)	(79,613)	(23,039)
Unrealized (loss) gain on investment, net of income taxes	(37)	67	(34)	63
Foreign currency translation adjustment, net of income taxes	181	(393)	680	(427)
Comprehensive loss	$ (38,481)	$ (12,747)	$ (78,967)	$ (23,403)
Net loss per share attributable to Athenex, Inc. common stockholders, basic and diluted	$ (0.88)	$ (0.31)	$ (1.89)	$ (0.59)
Weighted-average shares used in computing net loss per share attributable to Athenex, Inc. common stockholders, basic and diluted	43,741,096	39,775,112	42,208,612	39,321,739

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS EQUITY - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss	Treasury Stock	Total Athenex, Inc. Stockholders' Equity	Non-Controlling Interests
Beginning balance at Dec. 31, 2015	$ 98,044	$ 40	$ 206,679	$ (107,391)	$ (223)	$ (1,545)	$ 97,560	$ 484
Beginning balance, shares at Dec. 31, 2015		40,330,124				(422,328)
Issuance/sale of common stock	8,500	$ 1	8,499				8,500
Issuance/sale of common stock, shares		1,133,332
Issuance of common stock in connection with satisfaction of contingent consideration	2,843	$ 1	2,842				2,843
Issuance of common stock in connection with satisfaction of contingent consideration, shares		315,810
Stock-based compensation cost	3,877		3,877				3,877
Restricted stock expense	2,166		2,166				2,166
Repurchase of common stock, at cost	(2,216)					$ (2,216)	(2,216)
Repurchase of common stock, shares						(246,200)
Stock options exercised	14		14				14
Stock options exercised, shares		5,440
Non-controlling interests	519							519
Net loss	(23,149)			(23,039)			(23,039)	(110)
Other comprehensive income (loss), net of tax	(364)				(364)		(364)
Ending balance at Jun. 30, 2016	90,234	$ 42	224,077	(130,430)	(587)	$ (3,761)	89,341	893
Ending balance, shares at Jun. 30, 2016		41,784,706				(668,528)
Beginning balance at Dec. 31, 2016	34,669	$ 42	237,581	(195,106)	(1,304)	$ (7,406)	33,807	862
Beginning balance, shares at Dec. 31, 2016		42,342,706				(1,656,920)
Issuance/sale of common stock	64,194	$ 7	64,187				64,194
Issuance/sale of common stock, shares		6,900,000
Conversion of bonds	85,000	$ 8	84,992				85,000
Conversion of bonds, shares		7,727,273
Stock-based compensation cost	7,740		7,740				7,740
Stock-based compensation cost, shares		400,000
Research and development licensing fee satisfied with stock	6,250	$ 1	6,249				6,250
Research and development licensing fee satisfied with stock, shares		568,182
Vesting of restricted stock	1,080	$ 1	1,079				1,080
Vesting of restricted stock, shares		391,982
Stock options and warrants exercised	$ 439		439				439
Stock options and warrants exercised, shares		406,386
Repurchase of common stock, shares	(16,000)					(16,000)
Stock options exercised, shares	72,320
Non-controlling interests	$ 49							49
Net loss	(79,693)			(79,613)			(79,613)	(80)
Other comprehensive income (loss), net of tax	646				646		646
Ending balance at Jun. 30, 2017	$ 120,374	$ 59	$ 402,267	$ (274,719)	$ (658)	$ (7,406)	$ 119,543	$ 831
Ending balance, shares at Jun. 30, 2017		58,736,529				(1,672,920)

CONSOLIDATED STATEMENTS OF STO6

CONSOLIDATED STATEMENTS OF STOCKHOLDERS EQUITY (Parenthetical) $ in Thousands	6 Months Ended
	Jun. 30, 2017USD ($)
Statement Of Stockholders Equity [Abstract]
Stock issuance costs and discounts	$ 11,706

Condensed Consolidated Stateme7

Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Cash flows from operating activities:
Net loss	$ (79,693)	$ (23,149)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	1,664	752
Stock-based compensation expense	8,820	6,043
Change in fair value of contingent consideration		53
Change in fair value of derivative liability	8,863
Amortization of debt discount	3,040
Deferred rent expense	424
Loss on disposal of assets	80
Research and development license fees settled with convertible bond and stock	13,250
Interest incurred on converted bonds	3,350
Deferred income taxes	(108)	(435)
Changes in operating assets and liabilities, net of effects of acquisitions:
Receivables, net	(1,006)	32
Prepaid expenses and other assets	(824)	193
Inventories, net	(5,020)	(1,081)
Accounts payable and accrued expenses	(1,643)	(2,457)
Net cash used in operating activities	(48,803)	(20,049)
Cash flows from investing activities:
Purchase of property and equipment	(3,442)	(506)
Payment of refundable deposit		1,000
Payments for licenses	(1,550)
Purchases of short-term investments	(33,202)	(7,750)
Sale of short-term investments	11,657	6,900
Net cash used in investing activities	(26,537)	(356)
Cash flows from financing activities:
Proceeds from sale of stock	75,900	8,500
Proceeds from issuance of convertible bonds	30,000
Costs incurred related to the sale of stock	(9,044)
Proceeds from exercise of stock options	439	14
Investment from non-controlling interest	49	519
Payment of contingent consideration		(3,100)
Repayment of long-term debt	(553)	(536)
Purchase of treasury stock		(2,216)
Net cash provided by financing activities	96,791	3,181
Net increase (decrease) in cash and cash equivalents	21,451	(17,224)
Cash and cash equivalents, beginning of period	33,125	43,495
Effect of exchange rate changes on cash and cash equivalents	574	(131)
Cash and cash equivalents, end of period	55,150	26,140
Non-cash investing and financing activities:
Accrued purchases of property and equipment	80	76
Cost of equity raise in accounts payable and accrued expenses	1,124
Convertible bond issued in lieu of licensing cash payment	7,000
Common stock issued in lieu of licensing cash payment	6,250
Common stock issued upon the conversion of bonds	85,000
Property and equipment financed under capital lease	$ 234
QuaDPharma
Non-cash investing and financing activities:
Stock issued in connection with acquisition		343
Polymed
Non-cash investing and financing activities:
Stock issued in connection with acquisition		$ 2,500

Company and Nature of Business

Company and Nature of Business	6 Months Ended
	Jun. 30, 2017
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Company and Nature of Business	1. Company and Nature of Business Organization and Description of Business Athenex, Inc. (the “Company” or “Athenex”), originally under the name Kinex Pharmaceuticals LLC (“Kinex”), formed in November 2003, commenced operations on February 5, 2004, and operated as a limited liability company until it was incorporated in the State of Delaware under the name Kinex Pharmaceuticals, Inc. on December 31, 2012. The Company changed its name to Athenex, Inc. on August 26, 2015. Athenex is a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer. The Company’s mission is to improve the lives of cancer patients by creating more effective, safer and tolerable treatments. The Company has generated its clinical product candidates through its Orascovery and Src Kinase Inhibition research platforms, which are based on its understanding of human absorption biology and novel approaches to inhibiting kinase activity, respectively. The Company has assembled a leadership team and has established operations in the U.S. and China across the pharmaceutical value chain to execute its mission to become a global leader in bringing innovative cancer treatments to the market and improving health outcomes. The Company’s primary activities since commencement have been conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, and conducting clinical trials. Significant Risks and Uncertainties The Company has incurred operating losses since its inception and, as a result, as of December 31, 2016 and June 30, 2017 had an accumulated deficit of $195.1 million and $274.7 million, respectively. Operations have been funded primarily through the sale of common stock and convertible bonds and, to a lesser extent, through revenue generated from our Global Supply Chain Platform and Commercial Platform. The Company will require significant additional funds in order to conduct clinical trials and to fund its operations. There can be no assurances, however, that additional funding will be available on favorable terms, or at all. If adequate funds are not available, the Company may be required to delay, modify, or terminate its research and development programs or reduce its planned commercialization efforts. The Company believes that it will be able to obtain additional working capital through equity financings or other arrangements to fund operations; however, there can be no assurance that such additional financing, if available, can be obtained on terms acceptable to the Company. If the Company is unable to obtain such additional financing, the Company will need to reevaluate future operating plans. Accordingly, there is substantial doubt regarding the Company’s ability to continue as a going concern. These consolidated financial statements have been prepared on a going concern basis, which implies the Company will continue to realize its assets and discharge its liabilities in the normal course of the business. The Company’s recurring losses from operations and negative cash flows from operations have raised substantial doubt regarding its ability to continue as a going concern. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty. Athenex is subject to a number of risks similar to other biopharmaceutical companies, including, but not limited to, the lack of available capital, possible failure of preclinical testing or clinical trials, inability to obtain marketing approval of product candidates, competitors developing new technological innovations, market acceptance of the Company’s products, and protection of proprietary technology. If the Company does not successfully commercialize or partner any of its product candidates, it will be unable to generate sufficient product revenue to achieve profitability. Initial Public Offering On June 13, 2017, the Company’s Registration Statement on Form S-1 (File No. 333-217928) relating to the initial public offering (“IPO”) of its common stock was declared effective by the Securities and Exchange Commission (“SEC”). Pursuant to such Registration Statement, the Company sold an aggregate of 6,900,000 shares of its common stock at a price of $11.00 per share for cash proceeds of $64.2 million, net of underwriting discounts and commissions of $6.1 million and offering costs of $5.6 million. On June 14, 2017, the day of the IPO, convertible bonds with an aggregate principal value of $68.0 million, and a carrying value of $55.8 million, were converted into 7,727,273 shares of common stock. The IPO closed on June 19, 2017.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted in the United States of America for interim financial information (Accounting Standards Codification (“ASC”) 270, Interim Reporting ) and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these financial statements do not include all of the information necessary for a full presentation of financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States of America (“GAAP”). In the opinion of management, the condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments ) considered necessary for a fair presentation of the results of the Company for the periods presented. These condensed consolidated financial statements reflect the accounts and operations of the Company and those of its subsidiaries in which the Company has a controlling financial interest. Intercompany transactions and balances have been fully eliminated in consolidation. Results of the operations for the three and six months ended June 30, 2017 are not necessarily indicative of the results expected for the full fiscal year or for any future annual or interim period. These financial statements should be read in conjunction with the consolidated financial statements and related footnotes included in the Company’s Form S-1 covering the years ended December 31, 2015 and 2016. The Company’s accounting policies have not changed materially from those included in the Company’s Form S-1 covering the years ended December 31, 2015 and 2016, unless described herein. Use of Estimates These condensed consolidated financial statements have been prepared in conformity with GAAP. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the condensed consolidated financial statements and the reported amount of revenue and expenses during the reporting period. Such management estimates include those relating to assumptions used in contract research accruals, measurement of acquired assets and assumed liabilities in business combinations, allowance for doubtful accounts, inventory reserves, the valuation of derivative liability, income taxes, the estimated useful life and recoverability of long-lived assets, and the valuation of stock-based awards. Actual results could differ from those estimates. Revenue Recognition Product Sales, Chargebacks, Returns, and Discounts The Company recognizes product revenue when there is persuasive evidence of an arrangement, the price is fixed or determinable, collectability is reasonably assured, and upon shipment to or delivery and acceptance by customers. Service revenue is recognized in the period such services have been rendered. The Company’s specialty products sold through its Commercial Platform are distributed through independent pharmaceutical wholesalers. The wholesalers then generally sell to an end user, normally a hospital, alternative healthcare facility, or an independent pharmacy, at a lower price previously established by the end user and the Company. Sales are initially recorded at the list price sold to the wholesaler. Because these prices will be reduced for the end user, the Company records a contra-asset and reduction to revenue at the time of the sale, using the difference between the list price and the estimated end-user contract price. Upon the sale by the wholesaler to the end user, the wholesaler will chargeback the difference between the original list price and price at which the product was sold to the end user and such chargeback is offset against the initial estimated contra asset. The Company reviews the chargebacks to ensure that the initial list-price sales less the estimated chargebacks are accurate. As of June 30, 2017, the Company’s chargeback accrual totaled $1.5 million. The Company offers cash discounts, which approximate 2% of the gross sales price as an incentive for prompt customer payment, and, consistent with industry practice, the Company’s return policy permits customers to return products within a window of time before and after the expiration of product dating, most often 2% of gross purchases. The Company expects that its wholesale customers will make timely payments and take advantage of the cash discounts, and expects customers to use their right of return. Therefore, at the time of sale, net revenue and accounts receivable are reduced by the full amount of the discount offered and the return expected. The Company considers payment performance and historical return rates and adjusts the accrual to reflect actual experience. As of June 30, 2017, the Company’s accrual for cash discounts and return accrual were not material to the financial statements. Concentration of Credit Risk, Other Risks and Uncertainties Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and investments. Cash equivalents are deposited in interest-bearing money market accounts and certificates of deposit. Although the Company deposits the cash with multiple financial institutions, cash balances may occasionally be in excess of the amounts insured by the Federal Deposit Insurance Corporation. The Company also has significant assets and liabilities held in its overseas manufacturing facility in China, Taihao, and therefore is subject to foreign currency fluctuation. Also, due to government restrictions on transferring funds out of China, the total restricted net assets of the Company’s consolidated subsidiaries was $15.3 and $15.7 million as of June 30, 2017 and December 31, 2016, respectively. Recent Accounting Pronouncements Not Yet Adopted In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (“ASU”) No. 2014-09, “ Revenue from Contracts with Customers (Topic 606) In February 2016, the FASB issued ASU No. 2016-02, “ Leases (Topic 842) In June 2016, the FASB issued ASU No. 2016-13, “ Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments In November 2016, the FASB issued ASU 2016-18, “ Statement of Cash Flows (Topic 230): Restricted Cash Recently Adopted Accounting Pronouncements In July 2015, the FASB issued ASU No. 2015-11, “ Inventory (Topic 330): Simplifying the Measurement of Inventory. In March 2016, the FASB issued ASU No. 2016-09, “ Compensation—Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting In August 2016, the FASB issued ASU No. 2016-15, “ Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments In January 2017, the FASB issued ASU 201704, “ Intangibles—Goodwill and Other (Topic 350) Simplifying the Test for Goodwill Impairment

Inventories, Net

Inventories, Net	6 Months Ended
	Jun. 30, 2017
Inventory Disclosure [Abstract]
Inventories, Net	3. Inventories, net Inventories, net, consist of the following (in thousands): June 30, 2017 December 31, 2016 Raw materials and purchased parts $ 776 $ 977 Work in progress 3,792 2,727 Finished goods 4,692 536 Total inventories, net $ 9,260 $ 4,240

Intangible Assets, net

Intangible Assets, net	6 Months Ended
	Jun. 30, 2017
Goodwill And Intangible Assets Disclosure [Abstract]
Intangible Assets, net	4. Intangible Assets, net Intangible Assets, Net The Company’s identifiable intangible assets, net, consist of the following (in thousands): December 31, 2016 Cost/Fair Value Accumulated Amortization Impairments Net Amortizable intangible assets: Licenses $ 3,100 $ 315 $ - $ 2,785 QuaDPharma customer list 204 58 146 - Polymed customer list 1,593 414 - 1,179 Polymed technology 3,712 437 - 3,275 Indefinite-lived intangible assets: CDE in-process research and development (IPR&D) 1,884 - 248 1,636 Effect of currency translation adjustment (411 ) - - (411 ) Total intangible assets, net $ 10,082 $ 1,224 $ 394 $ 8,464 June 30, 2017 (unaudited) Cost/Fair Value Accumulated Amortization Impairments Net Amortizable intangible assets: Licenses $ 4,650 $ 731 $ - $ 3,919 QuaDPharma customer list - - - - Polymed customer list 1,593 545 - 1,048 Polymed technology 3,712 583 - 3,129 Indefinite-lived intangible assets: - CDE in-process research and development (IPR&D) 1,636 66 80 1,490 Effect of currency translation adjustment (405 ) (61 ) - (344 ) Total intangible assets, net $ 11,186 $ 1,864 $ 80 $ 9,242 As of December 31, 2016, licenses at cost include an Orascovery license of $0.4 million and a license purchased from Gland Pharma Ltd (“Gland”) of $2.7 million. The Orascovery license with Hanmi Pharmaceuticals Co. Ltd. (“Hanmi”) was purchased directly from Hanmi and is being amortized on a straight-line basis over a period of 12.75 years, the remaining life of the license agreement at the time of purchase. The license purchased from Gland is being amortized on a straight-line basis over a period of 5 years, the remaining life of the license agreement at the time of purchase. During the six months ended June 30, 2017, the Company purchased additional licenses from Gland for $1.6 million which are being amortized over a period of 5 years. The remaining intangible assets were acquired in connection with the acquisitions of Athenex Pharma Solutions (formerly referred to as QuaDPharma), Polymed, and CDE. Intangible assets are amortized using an economic consumption model over their useful lives. The Athenex Pharma Solutions customer list was being amortized on a straight-line basis over 7 years. The Polymed customer list and technology are amortized on a straight-line basis over 6 and 12 years, respectively. The CDE in-process research and development, or IPR&D, will not be amortized until the related projects are completed. IPR&D will be tested annually for impairment, unless conditions exist causing an earlier impairment test (i.e. abandonment of project). During the six months ended June 30, 2017, the Company abandoned a project within IPR&D and therefore, the related balance of $0.1 million was written-off as impaired and is included within research and development expenses in the condensed consolidated statement of operations and comprehensive loss for the six months ended June 30, 2017. The weighted-average useful life for all intangible assets was 7.87 years as of June 30, 2017. The Company recorded $0.4 million and $0.1 million of amortization expense for the three months ended June 30, 2017 and 2016, respectively, and $0.8 million and $0.3 million of amortization expense for the six months ended June 30, 2017 and 2016, respectively.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2017
Fair Value Disclosures [Abstract]
Fair Value Measurements	5. Fair Value Measurements Financial instruments consist of cash and cash equivalents, short-term investments, an equity investment, accounts receivable, accounts payable, accrued liabilities, and debt. Short-term investments, the equity investment, and the embedded derivative liability are stated at fair value. Cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities, and debt, are stated at their carrying value, which approximates fair value due to the short time to the expected receipt or payment date of such amounts. ASC 820, Fair Value Measurements, establishes a framework for measuring fair value. That framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements). The three levels of the fair value hierarchy under the ASC 820 are described as follows: Level 1 —Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities inactive markets that the plan has the ability to access. Level 2 —Inputs to the valuation methodology include: • Quoted prices for similar assets or liabilities in active markets; • Quoted prices for identical or similar assets or liabilities in inactive markets; • Inputs other than quoted prices that are observable for the asset or liability; • Inputs that are derived principally from or corroborated by observable market data by correlation or other means; and • If the asset or liability has a specified (contractual) term, the level 2 input must be observable for substantially the full term of the asset or liability. Level 3 —Inputs to the valuation methodology are unobservable, supported by little or no market activity, and that are significant to the fair value measurement. Transfers between levels, if any, are recorded as of the beginning of the reporting period in which the transfer occurs; there were no transfers between Levels 1, 2 or 3 for any of the periods presented. The following tables represent the fair value hierarchy for those assets and liabilities that the Company measures at fair value on a recurring basis (in thousands): Fair Value Measurements at December 31, 2016 Using: Total Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets: Money market funds $ 6,522 $ 6,522 $ - $ - Short-term investments - certificates of deposit 8,628 8,628 - - Investment 340 340 - - Total assets $ 15,490 $ 15,490 $ - $ - Liabilities: Derivative liability $ 8,795 $ - $ - $ 8,795 Total liabilities $ 8,795 $ - $ - $ 8,795 Fair Value Measurements at June 30, 2017 (unaudited) Using: Total Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets: Money market funds $ 22,169 $ 22,169 $ - $ - Short-term investments - commercial paper 19,945 - 19,945 - Short-term investments - corporate notes 10,017 - 10,017 - Short-term investments - U.S. government bonds 17,177 - 17,177 - Investment 330 330 - - Total assets $ 69,638 $ 22,499 $ 47,139 $ - Liabilities: Derivative liability $ 1,632 $ - $ - $ 1,632 Total liabilities $ 1,632 $ - $ - $ 1,632 The Company classifies its certificates of deposit and money market funds within Level 1 because it uses quoted market prices to determine their fair value. The Company classifies its commercial paper, corporate notes, and U.S. government bonds within Level 2 because it uses quoted prices for identical or similar assets or liabilities in inactive markets and each has a specified term and all level 2 inputs are observable for substantially the full term of each instrument. The Company owns 68,000 shares of PharmaEssentia, a company publicly traded on the Taiwan OTC Exchange (“TWO”). As of June 30, 2017 and December 31, 2016, the Company’s investment in PharmaEssentia is valued at the closing price reported on the TWO. This investment is classified as a level 1 investment. The Company bifurcated the embedded derivative feature from its convertible bonds and recorded such as a long-term liability. The derivative liability was measured at fair value as of the issuance date and remeasured at fair value at the end of the reporting period. The liability is measured at fair value using level 3 inputs. The derivative liability is discussed further in Note 7— Debt . The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial instruments (in thousands): Derivative Liability Balance as of December 31, 2016 $ 8,795 Issuance of convertible bonds with embedded derivative 13,172 Change in fair value 8,863 Conversion of derivative liability to common stock (29,198 ) Balance as of June 30, 2017 (unaudited) $ 1,632

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2017
Income Tax Disclosure [Abstract]
Income Taxes	6. Income Taxes The Company did not record a provision for federal income taxes for the six months ended June 30, 2017 because it expects to generate a loss for the year ending December 31, 2017 and the Company’s net deferred tax assets continue to be offset by a full valuation allowance. Tax benefit to date relates to foreign tax benefit on losses in the Peoples Republic of China (“PRC”) offset by state franchise taxes and amortization of long-lived intangible assets in the U.S. and PRC.

Debt

Debt	6 Months Ended
	Jun. 30, 2017
Debt Disclosure [Abstract]
Debt	7. Debt As of June 30, 2017 and December 31, 2016, the balances of this debt are as follows (in thousands): June 30, 2017 December 31, 2016 (unaudited) Current portion of promissory notes to related parties $ 1,064 $ 1,123 Current portion of mortgage 789 766 Current portion of capital lease obligation 43 - Long-term portion of promissory notes to related parties - 496 Long-term portion of capital lease obligation 191 - Convertible bonds 5,042 14,498 Convertible bonds - related parties - 16,129 Derivative liability 1,632 8,795 Total $ 8,761 $ 41,807 The promissory notes have a 36-month term beginning on July 1, 2015 and ending on June 1, 2018 with a 6% stated interest rate. The mortgage payments extend through July 30, 2017. Future minimum principal payments on these promissory notes and mortgage consist of $1.4 million and $0.5 million due in the remaining six months in 2017 and 2018, respectively. In 2016 and 2017, the Company issued convertible bonds with an aggregate principal value of $75.0 million and a maturity date of October 1, 2018. Of the convertible bonds issued, an aggregate principal of $24.0 million were issued to related parties. On June 14, 2017, the IPO date, $68.0 million of these bonds, which had a carrying value of $55.8 million, were converted into 7,727,273 shares of common stock. In March 2017, the Company signed an amendment to its license agreement with Hanmi, under which the Company received the rights to develop and sell drugs under the Orascovery program in additional territories, including Japan. This license amendment required an upfront fee of $7.0 million payable to Hanmi upon the execution of the agreement. In lieu of the payment, the Company issued a convertible bond to Hanmi with a par value of $7.0 million. This bond carries an interest rate of 10% per annum and a maturity date of October 1, 2018. Hanmi has the option to convert the bond to shares of common stock at discounted rates from 20% to 22% at various dates up to the maturity date. This amendment includes additional regulatory milestone payments and royalties based on sales. The occurrence of any milestone triggering events have not been deemed to be probable and no sales have yet occurred. Hanmi did not elect to convert this bond into common stock on the IPO date.

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2017
Related Party Transactions [Abstract]
Related Party Transactions	8. Related Party Transactions During the three and six months ended June 30, 2017 and 2016, the Company entered into transactions with individuals and other companies that have financial interests in the Company. Related party transactions included the following: a. The Company sold 2,520,000 shares of restricted stock to the executives of the Company: 1,200,000 in 2015 and 1,320,000 in 2014. To fund these stock purchases, the executives signed promissory notes in the amount of $6.6 million in 2015 and $6.0 million in 2014. The notes in 2015 purchased 1,200,000 shares at $5.50 share and the notes in 2014 purchased 1,320,000 shares at $4.55 per share. In an effort to retain the executives, it was negotiated that, based on the continued employment of those executives, the Company will forgive the notes over a three year period. Accordingly, the restricted shares vest and become non-restricted equally over the three-year period. The Company has accounted for this related party transaction as a restricted stock offering, recognizing as an expense the value of the vested shares and the forgiveness of the notes over the three-year period, contingent on the continued employment of the executive. The notes are reported as a reduction to additional paid-in capital. The Company accelerated the forgiveness of these promissory notes in 2016 and forgave the notes in full. The stock-based compensation expense recognized from these transactions was $0 and $1.0 million, for the three months ended June 30, 2017 and 2016, respectively, and $0 and $2.1 million for the six months ended June 30, 2017 and 2016, respectively. b. In 2015, CDE signed an agreement with Avalon BioMedical (Management) (“Avalon”) under which Avalon will receive certain administrative services and will occupy space at CDE’s research location. Avalon reimburses CDE for these administrative services as incurred and pays CDE 30% of the total rent payment for the Hong Kong research and development facility (See Note 13— Commitments and Contingencies c. The Company receives consulting and licensing revenue from PharmaEssentia, a company in which Athenex has an investment classified as available-for-sale (see Note 5— Fair Value Measurements d. The Company purchases certain pharmaceutical ingredients from Chongqing Taisheng Biotechnology Co., Ltd. (“Taisheng”), a company which is owned by a member of Athenex’s management. Purchases from Taisheng amounted to $0 for both the three months ended June 30, 2017 and 2016, and $0, and $0.2 million for the six months ended June 30, 2017 and 2016, respectively. Amounts owed to Taisheng were $0 as of June 30, 2017 and December 31, 2016. e. The Company receives certain clinical development services from ZenRx Limited and subsidiaries (“ZenRx”), a company for which one of our executive officers serves on the board of directors. In connection with such services, the Company made payments to ZenRx of $0.1 million and less than $0.1 million during the three months ended June 30, 2017 and 2016, respectively, and $0.2 million and less than $0.1 million during the six months ended June 30, 2017 and 2016, respectively. As of June 30, 2017 and December 31, 2016, amounts owed to ZenRx were less than $0.1 million and $0.1 million, respectively. In April 2013, the Company entered into a license agreement with ZenRx pursuant to which the Company granted an exclusive, sublicensable license to use certain of our intellectual property to develop and commercialize Oratecan and Oraxol in Australia and New Zealand, and a non-exclusive license to manufacture a certain compound, but only for use in Oratecan and Oraxol. ZenRx is responsible for all development, manufacturing and commercialization, and the related costs and expenses, of any product candidates resulting from the agreement. No revenue was earned from this license agreement in the periods presented in these condensed consolidated financial statements. f. The Company receives certain consulting services from RSJ Consulting LLC (“RSJ”), a limited liability company for which one of our executive officers serves as the principal. Services incurred from RSJ amounted to less than $0.1 million and less than $0.1 million for the three months ended June 30, 2017 and 2016, respectively, and $0.1 million and $0.2 million for the six months ended June 30, 2017 and 2016, respectively. g. The Company issued and sold $24.0 million in convertible bonds in 2016 and 2017 to related parties. One of the holders of more than 5% of our outstanding common stock as of December 31, 2016, and an entity affiliated with one of our directors, each purchased $10.0 million in convertible bonds during 2016. Additionally, during the first quarter of 2017, the Company issued and sold $4.0 million in convertible bonds to two related parties. One of the holders of more than 5% of our outstanding common stock as of March 31, 2017 and a director of the Company each purchased $2.0 million in convertible bonds. On June 14, 2017, the IPO date, these bonds were converted into 2,727,273 shares of common stock.

Stockholders Equity

Stockholders Equity	6 Months Ended
	Jun. 30, 2017
Equity [Abstract]
Stockholders’ Equity	9. Stockholders’ Equity Common Stock As of June 30, 2017 and 2016, 250 million common shares, par value $0.001, were authorized by the Company’s Board of Directors. The common shares are entitled to one vote per share and to receive dividends as declared. On June 14, 2017, the Company completed an IPO of its common stock (refer to Note 1 – Company and Nature of Business for additional information). During the six months ended June 30, 2017, the Company issued 6,900,000 shares of common stock at $11.00 per share in connection with the IPO, 7,727,273 shares of common stock from the conversion of the convertible bonds into common stock, 568,182 shares of common stock upon the IPO in connection with a licensing agreements, 406,386 shares from the exercise of warrants and options, and 791,982 shares from the vesting of restricted stock units and the grant of shares in connection with an executive’s employment agreement for cumulative increase to equity of $164.7 million. Treasury Stock During the six months ended June 30, 2017, the Company purchased 16,000 shares of common stock for a de minimis amount as the result of the cancellation of shares issued in connection with a restricted stock agreement. Cost of Equity Raise Costs incurred in raising equity, whether paid with cash or through the issuance of securities, are charged against the equity raised. These costs include underwriting discounts and commissions, legal fees, accounting services and amounts paid to consultants and amounted to $11.7 million, cumulatively, as of the IPO date. $1.8 million of these costs were deferred and included within other long-term assets on the consolidated balance sheet as of December 31, 2016. The total amount of $11.7 million was charged against the capital raised through the IPO. Common Stock Option Plans The Company has three common stock option plans adopted in 2013, 2007 and 2004 (the “Plans”) which authorize the grant of up to 11,800,000 common stock options to employees, directors, and consultants. Additionally, on June 14, 2017, the Company adopted its 2017 Omnibus Incentive Plan and 2017 Employee Stock Purchase Plan (the “2017 Plans”). Under the 2017 Plans, 5,200,000 shares of common stock are reserved for future issuance to employees, directors, and consultants, including 1,000,000 reserved for an Employee Stock Purchase Plan, which was established at IPO but no shares have as yet been issued. Management has valued the options at their grant date using the Black-Scholes option pricing model. See Note 10— Stock-Based Compensation for more information.

Stock Based Compensation

Stock Based Compensation	6 Months Ended
	Jun. 30, 2017
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock Based Compensation	10. Stock-Based Compensation Stock Options The Company recognizes stock-based compensation based on the grant date fair value of stock options granted to employees, officers, and directors. The Company uses the Black-Scholes option pricing model to calculate the grant date fair value of stock options and warrants. The Black-Scholes option pricing model requires inputs for risk-free interest rate, dividend yield, volatility, fair value of common stock, and expected lives of the options. The risk-free rate for periods within the expected life of the option is based on the U.S. Treasury yield curve in effect at the time of the grant. No dividend yield is used, consistent with the Company’s history. Expected volatility is based on historical volatilities of the stock prices of peer biopharmaceutical companies. Historically, the fair value of common stock has been based on the most recent sale price of the Company’s common stock and is now valued based on market price at the date of issuance. The Company uses the simplified method for determining the expected lives of options. The Company recognizes compensation expenses based on the grant date fair value of stock options on a straight-line basis over the requisite service period, which is generally the vesting period. Options granted have a contractual term of 10 years and generally vest over a 2-4 year period. A limited number of options vest immediately in certain circumstances. The following table summarizes the status of the Company’s stock option activity granted under the Plans to employees, directors, and consultants (in thousands, except stock option amounts): Stock Options Weighted- Average Exercise price Weighted- Average Remaining Contractual Term Aggregate Intrinsic Value Outstanding at December 31, 2016 9,280,689 $ 6.26 7.26 $ 43,994 Granted 1,626,532 11.00 - Exercised (72,320 ) 6.06 - Forfeited (70,042 ) 9.29 - Expired (9,273 ) 3.54 - Outstanding at June 30, 2017 (unaudited) 10,755,586 $ 6.96 7.25 $ 99,376 Vested and exercisable at June 30, 2017 (unaudited) 7,547,480 $ 5.85 6.46 $ 78,092 The total fair-value of stock options vested and recorded as compensation expense during the three months ended June 30, 2017 and 2016 and the six months ended June 30, 2017 and 2016 was $1.7 million, $2.0 million, $3.3 million, and $3.9 million, respectively. As of June 30, 2017 and December 31, 2016, $17.9 million and $11.0 million of unrecognized cost related to non-vested stock options is expected to be recognized over a weighted-average period of approximately 1.9 years and 1.6 years, respectively. The total intrinsic value of options exercised was approximately $0.4 million and less than $0.1 million for the six months ended June 30, 2017 and 2016, respectively. The Company determines the fair value of stock-based awards on the grant date using the Black-Scholes option pricing model, which is impacted by assumptions regarding a number of highly subjective variables. The following table summarizes the weighted-average assumptions used as inputs to the Black-Scholes model during the periods indicated: Six months ended Six months ended June 30, 2017 June 30, 2016 Weighted average grant date fair value $ 6.49 $ 5.29 Expected dividend yield - % - % Expected stock price volatility 66 % 65 % Risk-free interest rate 1.74 % 1.20 % Expected life of options (in years) 6.2 6.0 Stock Grants The Company grants common stock to key officers and directors as additional compensation in certain circumstances. The fair value of these grants is recorded as compensation expense throughout the requisite service period. Compensation cost recorded for the stock grants amounted to $4.4 million and $1.0 million for the three months ended June 30, 2017 and 2016, respectively, and $4.4 million and $2.1 million for the six months ended June 30, 2017 and 2016, respectively. Awards granted to non-employees The Company has accounted for equity instruments issued to non-employees in accordance with the provisions of ASC 718, Compensation—Stock Compensation Equity Restricted Stock The following table summarizes restricted stock activity: Shares of Restricted Stock Weighted Average Fair Value Nonvested at December 31, 2016 661,982 $ 9.00 Granted - 9.00 Vested (391,982 ) 9.00 Nonvested at June 30, 2017 (unaudited) 270,000 $ 9.00 Warrants The Company has granted warrants to purchase common stock. The Company determined the fair value of the warrants on the grant date using the Black-Scholes option pricing model, consistent with the valuations of stock options described above. All warrants were fully vested and 344,000 were outstanding as of December 31, 2016. During June 2017, the holder exercised their warrants and as of June 30, 2017, there were no outstanding warrants. Stock-Based Compensation Cost The components of stock-based compensation and the amounts recorded within research and development expenses and selling, general, and administrative expenses in the Company’s consolidated statements of operations and comprehensive loss consisted of the following for the three and six months ended June 30, 2017 and 2016 (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 Stock options $ 1,736 $ 2,013 $ 3,340 $ 3,877 Vesting of restricted stock grants 540 1,120 1,080 2,166 Stock awarded to directors and officers 4,400 - 4,400 - Total stock-based compensation expense $ 6,676 $ 3,133 $ 8,820 $ 6,043 Cost of product sales $ 26 $ - $ 48 $ - Research and development expenses 447 1,610 908 3,165 Selling, general, and administrative expenses 6,203 1,523 7,864 2,878 Total stock-based compensation expense $ 6,676 $ 3,133 $ 8,820 $ 6,043

Net Loss Per Share Attributable

Net Loss Per Share Attributable to Athenex, Inc. Common Stockholders	6 Months Ended
	Jun. 30, 2017
Earnings Per Share [Abstract]
Net Loss Per Share Attributable to Athenex, Inc. Common Stockholders	11. Net Loss Per Share Attributable to Athenex, Inc. Common Stockholders Basic net loss per share is calculated by dividing net loss attributable to common stockholders by the weighted-average number of common shares issued, outstanding, and vested during the period. Diluted net loss per share is computed by dividing net loss attributable to common stockholders by the weighted-average number of common share and common shares equivalents for the period using the treasury-stock method. For the purposes of this calculation, warrants for common stock and stock options are considered common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive. The following outstanding shares of common stock equivalents were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been antidilutive: Three Months Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 (unaudited) Stock options and other common stock equivalents 9,819,089 11,136,500 9,749,264 11,016,552 Unvested restricted shares 596,651 1,053,887 629,317 1,158,887 Total potential dilutive shares 10,415,740 12,190,387 10,378,581 12,175,439

Business Segment, Geographic, a

Business Segment, Geographic, and Concentration Risk Information	6 Months Ended
	Jun. 30, 2017
Segment Reporting [Abstract]
Business Segment, Geographic, and Concentration Risk Information	12. Business Segment, Geographic, and Concentration Risk Information The Company has three operating segments, which are organized based mainly on the nature of the business activities performed and regulatory environments in which they operate. The Company also considers the types of products from which the reportable segments derive their revenue (only applicable to two reportable segments). Each operating segment has a segment manager who is held accountable for operations and has discrete financial information that is regularly reviewed by the Company’s chief operating decision-maker. The Company’s operating segments are as follows: Oncology Innovation Platform —This primary operating segment performs research and development on certain of the Company’s proprietary drugs, from the preclinical development of its chemical compounds, to the execution and analysis of its several clinical trials. This segment focuses specifically on the oral absorption cancer drug platform, the Src Kinase inhibitors, and the transmucosal drug delivery system. This segment performs research in the United States, Taiwan, Hong Kong, and mainland China. Global Supply Chain Platform —This operating segment includes Athenex Pharma Solutions and Polymed. Athenex Pharma Solutions is a contract manufacturing company that provides small to mid-scale cGMP manufacturing of clinical and commercial products for pharmaceutical and biotech companies. Athenex Pharma Solutions also performs microbiological and analytical testing for raw material and formulated products and is expanding to manufacture and sell pharmaceutical products under 503B regulations set forth by the U.S. Food and Drug Administration (“FDA”). Polymed markets and sells API and medical devices in North America, Europe, and Asia from its locations in Texas and China. Polymed also develops new compounds, processing techniques, and manufactures API at Taihao, a cGMP facility in Chongqing, China. Currently, a majority of the Company’s revenue is generated by this segment. Commercial Platform —This operating segment includes Athenex Pharmaceutical Division, a newly-formed component that is focused on the manufacturing, distribution, and sales of generic pharmaceuticals. This segment provides services and products to external customers based mainly in the United States. The segments operate in North America and Asia. The Company’s Oncology Innovation Platform segment operates and holds long-lived assets located in the United States, Taiwan, Hong Kong, and mainland China. The Commercial Platform segment operates and holds long-lived assets located in the United States. The Global Supply Chain Platform segment operates and holds long-lived assets located in the United States and China. For geographic segment reporting, product sales have been attributed to countries based on the location of the customer. Segment information is as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 (unaudited) (unaudited) Net (loss) income attributable to Athenex, Inc.: Oncology Innovation Platform $ (33,018 ) $ (12,037 ) $ (61,277 ) $ (22,452 ) Global Supply Chain Platform (1,981 ) 428 (3,129 ) 225 Commercial Platform (3,626 ) (812 ) (15,207 ) (812 ) Total consolidated net loss attributable to Athenex, Inc. $ (38,625 ) $ (12,421 ) $ (79,613 ) $ (23,039 ) Three Months Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 (unaudited) (unaudited) Total revenue: Oncology Innovation Platform $ 270 $ 404 $ 1,003 $ 546 Global Supply Chain Platform 4,509 6,249 10,806 11,605 Commercial Platform 1,820 - 1,896 - Total revenue for reportable segments 6,599 6,653 13,705 12,151 Intersegment revenue (2,004 ) (1,460 ) (4,529 ) (2,329 ) Total consolidated revenue $ 4,595 $ 5,193 $ 9,176 $ 9,822 Three Months Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 (unaudited) (unaudited) Total revenue by product group: API sales $ 2,024 $ 3,726 $ 5,023 $ 7,688 Medical device sales 232 519 567 876 Contract manufacturing revenue 247 544 684 712 Commercial product sales 1,913 31 2,042 32 License fees and consulting revenue 98 71 696 166 Grant revenue 81 302 164 348 Total consolidated revenue $ 4,595 $ 5,193 $ 9,176 $ 9,822 Intersegment revenue is recorded by the selling segment when it is realized or realizable and all revenue recognition criteria are met. Upon consolidation, all intersegment revenue and related cost of sales are eliminated from the selling segment’s ledger. Three Months Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 (unaudited) (unaudited) Total depreciation and amortization: Oncology Innovation Platform $ 120 $ 51 $ 212 $ 98 Global Supply Chain Platform 495 284 1,021 654 Commercial Platform 233 - 431 - Total consolidated depreciation and amortization $ 848 $ 335 $ 1,664 $ 752 June 30, December 31, 2017 2016 (unaudited) Total assets: Oncology Innovation Platform $ 97,562 $ 53,022 Global Supply Chain Platform 47,052 48,560 Commercial Platform 13,200 4,308 Total consolidated assets $ 157,814 $ 105,890 Three Months Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 (unaudited) (unaudited) Total revenue: United States $ 2,227 $ 1,011 $ 2,940 $ 1,513 India 790 1,252 2,261 3,208 Austria 716 1,792 1,718 3,184 China 417 655 729 1,111 Taiwan - - 500 - Other foreign countries 445 483 1,028 806 Total consolidated revenue $ 4,595 $ 5,193 $ 9,176 $ 9,822 June 30, December 31, 2017 2016 (unaudited) Total property and equipment, net: United States $ 4,280 $ 2,177 China 4,041 3,633 Total consolidated property and equipment, net $ 8,321 $ 5,810 Customer revenue and accounts receivable concentration amounted to the following for the identified periods. All customers relate to the Global Supply Chain Platform Segment. Three Months Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 (unaudited) (unaudited) Percentage of total revenue by customer: Customer A 17 % 24 % 22 % 33 % Customer B 15 % 31 % 18 % 31 % June 30, December 31, 2017 2016 (unaudited) Percentage of total accounts receivable by customer: Customer A 19 % 50 % Customer B 9 % 9 %

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2017
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	13. Commitments and Contingencies Future minimum payments under the non-cancelable leases consists of the following as of June 30, 2017 (in thousands): Year ending December 31: Minimum payments 2017 (remaining six months) $ 473 2018 1,298 2019 1,650 2020 1,659 2021 1,668 Thereafter 6,202 $ 12,950 Legal Proceedings The Company is not a party to any pending or known threatened legal proceedings that, in the opinion of the Company, would have a material impact on the Company’s condensed consolidated financial statements.

Summary of Significant Accoun21

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted in the United States of America for interim financial information (Accounting Standards Codification (“ASC”) 270, Interim Reporting ) and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these financial statements do not include all of the information necessary for a full presentation of financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States of America (“GAAP”). In the opinion of management, the condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments ) considered necessary for a fair presentation of the results of the Company for the periods presented. These condensed consolidated financial statements reflect the accounts and operations of the Company and those of its subsidiaries in which the Company has a controlling financial interest. Intercompany transactions and balances have been fully eliminated in consolidation. Results of the operations for the three and six months ended June 30, 2017 are not necessarily indicative of the results expected for the full fiscal year or for any future annual or interim period. These financial statements should be read in conjunction with the consolidated financial statements and related footnotes included in the Company’s Form S-1 covering the years ended December 31, 2015 and 2016. The Company’s accounting policies have not changed materially from those included in the Company’s Form S-1 covering the years ended December 31, 2015 and 2016, unless described herein.
Use of Estimates	Use of Estimates These condensed consolidated financial statements have been prepared in conformity with GAAP. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the condensed consolidated financial statements and the reported amount of revenue and expenses during the reporting period. Such management estimates include those relating to assumptions used in contract research accruals, measurement of acquired assets and assumed liabilities in business combinations, allowance for doubtful accounts, inventory reserves, the valuation of derivative liability, income taxes, the estimated useful life and recoverability of long-lived assets, and the valuation of stock-based awards. Actual results could differ from those estimates.
Revenue Recognition	Revenue Recognition Product Sales, Chargebacks, Returns, and Discounts The Company recognizes product revenue when there is persuasive evidence of an arrangement, the price is fixed or determinable, collectability is reasonably assured, and upon shipment to or delivery and acceptance by customers. Service revenue is recognized in the period such services have been rendered. The Company’s specialty products sold through its Commercial Platform are distributed through independent pharmaceutical wholesalers. The wholesalers then generally sell to an end user, normally a hospital, alternative healthcare facility, or an independent pharmacy, at a lower price previously established by the end user and the Company. Sales are initially recorded at the list price sold to the wholesaler. Because these prices will be reduced for the end user, the Company records a contra-asset and reduction to revenue at the time of the sale, using the difference between the list price and the estimated end-user contract price. Upon the sale by the wholesaler to the end user, the wholesaler will chargeback the difference between the original list price and price at which the product was sold to the end user and such chargeback is offset against the initial estimated contra asset. The Company reviews the chargebacks to ensure that the initial list-price sales less the estimated chargebacks are accurate. As of June 30, 2017, the Company’s chargeback accrual totaled $1.5 million. The Company offers cash discounts, which approximate 2% of the gross sales price as an incentive for prompt customer payment, and, consistent with industry practice, the Company’s return policy permits customers to return products within a window of time before and after the expiration of product dating, most often 2% of gross purchases. The Company expects that its wholesale customers will make timely payments and take advantage of the cash discounts, and expects customers to use their right of return. Therefore, at the time of sale, net revenue and accounts receivable are reduced by the full amount of the discount offered and the return expected. The Company considers payment performance and historical return rates and adjusts the accrual to reflect actual experience. As of June 30, 2017, the Company’s accrual for cash discounts and return accrual were not material to the financial statements.
Concentration of Credit Risk, Other Risks and Uncertainties	Concentration of Credit Risk, Other Risks and Uncertainties Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and investments. Cash equivalents are deposited in interest-bearing money market accounts and certificates of deposit. Although the Company deposits the cash with multiple financial institutions, cash balances may occasionally be in excess of the amounts insured by the Federal Deposit Insurance Corporation. The Company also has significant assets and liabilities held in its overseas manufacturing facility in China, Taihao, and therefore is subject to foreign currency fluctuation. Also, due to government restrictions on transferring funds out of China, the total restricted net assets of the Company’s consolidated subsidiaries was $15.3 and $15.7 million as of June 30, 2017 and December 31, 2016, respectively.
Recent Accounting Pronouncements Not Yet Adopted	Recent Accounting Pronouncements Not Yet Adopted In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (“ASU”) No. 2014-09, “ Revenue from Contracts with Customers (Topic 606) In February 2016, the FASB issued ASU No. 2016-02, “ Leases (Topic 842) In June 2016, the FASB issued ASU No. 2016-13, “ Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments In November 2016, the FASB issued ASU 2016-18, “ Statement of Cash Flows (Topic 230): Restricted Cash
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements In July 2015, the FASB issued ASU No. 2015-11, “ Inventory (Topic 330): Simplifying the Measurement of Inventory. In March 2016, the FASB issued ASU No. 2016-09, “ Compensation—Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting In August 2016, the FASB issued ASU No. 2016-15, “ Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments In January 2017, the FASB issued ASU 201704, “ Intangibles—Goodwill and Other (Topic 350) Simplifying the Test for Goodwill Impairment

Inventories, Net (Tables)

Inventories, Net (Tables)	6 Months Ended
	Jun. 30, 2017
Inventory Disclosure [Abstract]
Schedule of Inventories, Net	Inventories, net, consist of the following (in thousands): June 30, 2017 December 31, 2016 Raw materials and purchased parts $ 776 $ 977 Work in progress 3,792 2,727 Finished goods 4,692 536 Total inventories, net $ 9,260 $ 4,240

Intangible Assets, net (Tables)

Intangible Assets, net (Tables)	6 Months Ended
	Jun. 30, 2017
Goodwill And Intangible Assets Disclosure [Abstract]
Summary of Identifiable Intangible Asset, Net	The Company’s identifiable intangible assets, net, consist of the following (in thousands): December 31, 2016 Cost/Fair Value Accumulated Amortization Impairments Net Amortizable intangible assets: Licenses $ 3,100 $ 315 $ - $ 2,785 QuaDPharma customer list 204 58 146 - Polymed customer list 1,593 414 - 1,179 Polymed technology 3,712 437 - 3,275 Indefinite-lived intangible assets: CDE in-process research and development (IPR&D) 1,884 - 248 1,636 Effect of currency translation adjustment (411 ) - - (411 ) Total intangible assets, net $ 10,082 $ 1,224 $ 394 $ 8,464 June 30, 2017 (unaudited) Cost/Fair Value Accumulated Amortization Impairments Net Amortizable intangible assets: Licenses $ 4,650 $ 731 $ - $ 3,919 QuaDPharma customer list - - - - Polymed customer list 1,593 545 - 1,048 Polymed technology 3,712 583 - 3,129 Indefinite-lived intangible assets: - CDE in-process research and development (IPR&D) 1,636 66 80 1,490 Effect of currency translation adjustment (405 ) (61 ) - (344 ) Total intangible assets, net $ 11,186 $ 1,864 $ 80 $ 9,242

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2017
Fair Value Disclosures [Abstract]
Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis	The following tables represent the fair value hierarchy for those assets and liabilities that the Company measures at fair value on a recurring basis (in thousands): Fair Value Measurements at December 31, 2016 Using: Total Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets: Money market funds $ 6,522 $ 6,522 $ - $ - Short-term investments - certificates of deposit 8,628 8,628 - - Investment 340 340 - - Total assets $ 15,490 $ 15,490 $ - $ - Liabilities: Derivative liability $ 8,795 $ - $ - $ 8,795 Total liabilities $ 8,795 $ - $ - $ 8,795 Fair Value Measurements at June 30, 2017 (unaudited) Using: Total Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets: Money market funds $ 22,169 $ 22,169 $ - $ - Short-term investments - commercial paper 19,945 - 19,945 - Short-term investments - corporate notes 10,017 - 10,017 - Short-term investments - U.S. government bonds 17,177 - 17,177 - Investment 330 330 - - Total assets $ 69,638 $ 22,499 $ 47,139 $ - Liabilities: Derivative liability $ 1,632 $ - $ - $ 1,632 Total liabilities $ 1,632 $ - $ - $ 1,632
Summary of Changes in Fair Value of Company's Level 3 Financial Instruments	The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial instruments (in thousands): Derivative Liability Balance as of December 31, 2016 $ 8,795 Issuance of convertible bonds with embedded derivative 13,172 Change in fair value 8,863 Conversion of derivative liability to common stock (29,198 ) Balance as of June 30, 2017 (unaudited) $ 1,632

Debt (Tables)

Debt (Tables)	6 Months Ended
	Jun. 30, 2017
Debt Disclosure [Abstract]
Components of Debt	As of June 30, 2017 and December 31, 2016, the balances of this debt are as follows (in thousands): June 30, 2017 December 31, 2016 (unaudited) Current portion of promissory notes to related parties $ 1,064 $ 1,123 Current portion of mortgage 789 766 Current portion of capital lease obligation 43 - Long-term portion of promissory notes to related parties - 496 Long-term portion of capital lease obligation 191 - Convertible bonds 5,042 14,498 Convertible bonds - related parties - 16,129 Derivative liability 1,632 8,795 Total $ 8,761 $ 41,807

Stock Based Compensation (Table

Stock Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2017
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Schedule of Stock Option Activity	The following table summarizes the status of the Company’s stock option activity granted under the Plans to employees, directors, and consultants (in thousands, except stock option amounts): Stock Options Weighted- Average Exercise price Weighted- Average Remaining Contractual Term Aggregate Intrinsic Value Outstanding at December 31, 2016 9,280,689 $ 6.26 7.26 $ 43,994 Granted 1,626,532 11.00 - Exercised (72,320 ) 6.06 - Forfeited (70,042 ) 9.29 - Expired (9,273 ) 3.54 - Outstanding at June 30, 2017 (unaudited) 10,755,586 $ 6.96 7.25 $ 99,376 Vested and exercisable at June 30, 2017 (unaudited) 7,547,480 $ 5.85 6.46 $ 78,092
Schedule of Weighted Average Assumptions Used as Inputs to Black-Scholes Model	The following table summarizes the weighted-average assumptions used as inputs to the Black-Scholes model during the periods indicated: Six months ended Six months ended June 30, 2017 June 30, 2016 Weighted average grant date fair value $ 6.49 $ 5.29 Expected dividend yield - % - % Expected stock price volatility 66 % 65 % Risk-free interest rate 1.74 % 1.20 % Expected life of options (in years) 6.2 6.0
Schedule of Restricted Stock Activity	The following table summarizes restricted stock activity: Shares of Restricted Stock Weighted Average Fair Value Nonvested at December 31, 2016 661,982 $ 9.00 Granted - 9.00 Vested (391,982 ) 9.00 Nonvested at June 30, 2017 (unaudited) 270,000 $ 9.00
Schedule of Stock-Based Compensation Cost	The components of stock-based compensation and the amounts recorded within research and development expenses and selling, general, and administrative expenses in the Company’s consolidated statements of operations and comprehensive loss consisted of the following for the three and six months ended June 30, 2017 and 2016 (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 Stock options $ 1,736 $ 2,013 $ 3,340 $ 3,877 Vesting of restricted stock grants 540 1,120 1,080 2,166 Stock awarded to directors and officers 4,400 - 4,400 - Total stock-based compensation expense $ 6,676 $ 3,133 $ 8,820 $ 6,043 Cost of product sales $ 26 $ - $ 48 $ - Research and development expenses 447 1,610 908 3,165 Selling, general, and administrative expenses 6,203 1,523 7,864 2,878 Total stock-based compensation expense $ 6,676 $ 3,133 $ 8,820 $ 6,043

Net Loss Per Share Attributab27

Net Loss Per Share Attributable to Athenex, Inc. Common Stockholders (Tables)	6 Months Ended
	Jun. 30, 2017
Earnings Per Share [Abstract]
Schedule Outstanding Shares of Common Stock Equivalents Excluded from the Calculation of Diluted Net Loss Per Share	The following outstanding shares of common stock equivalents were excluded from the calculation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been antidilutive: Three Months Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 (unaudited) Stock options and other common stock equivalents 9,819,089 11,136,500 9,749,264 11,016,552 Unvested restricted shares 596,651 1,053,887 629,317 1,158,887 Total potential dilutive shares 10,415,740 12,190,387 10,378,581 12,175,439

Business Segment, Geographic,28

Business Segment, Geographic, and Concentration Risk Information (Tables)	6 Months Ended
	Jun. 30, 2017
Segment Reporting [Abstract]
Summary of Segment Information	Segment information is as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 (unaudited) (unaudited) Net (loss) income attributable to Athenex, Inc.: Oncology Innovation Platform $ (33,018 ) $ (12,037 ) $ (61,277 ) $ (22,452 ) Global Supply Chain Platform (1,981 ) 428 (3,129 ) 225 Commercial Platform (3,626 ) (812 ) (15,207 ) (812 ) Total consolidated net loss attributable to Athenex, Inc. $ (38,625 ) $ (12,421 ) $ (79,613 ) $ (23,039 )
Summary of Revenue by Segments	Three Months Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 (unaudited) (unaudited) Total revenue: Oncology Innovation Platform $ 270 $ 404 $ 1,003 $ 546 Global Supply Chain Platform 4,509 6,249 10,806 11,605 Commercial Platform 1,820 - 1,896 - Total revenue for reportable segments 6,599 6,653 13,705 12,151 Intersegment revenue (2,004 ) (1,460 ) (4,529 ) (2,329 ) Total consolidated revenue $ 4,595 $ 5,193 $ 9,176 $ 9,822
Summary of Revenue by Product Group	Three Months Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 (unaudited) (unaudited) Total revenue by product group: API sales $ 2,024 $ 3,726 $ 5,023 $ 7,688 Medical device sales 232 519 567 876 Contract manufacturing revenue 247 544 684 712 Commercial product sales 1,913 31 2,042 32 License fees and consulting revenue 98 71 696 166 Grant revenue 81 302 164 348 Total consolidated revenue $ 4,595 $ 5,193 $ 9,176 $ 9,822
Summary of Depreciation, Amortization and Assets by Segment	Three Months Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 (unaudited) (unaudited) Total depreciation and amortization: Oncology Innovation Platform $ 120 $ 51 $ 212 $ 98 Global Supply Chain Platform 495 284 1,021 654 Commercial Platform 233 - 431 - Total consolidated depreciation and amortization $ 848 $ 335 $ 1,664 $ 752 June 30, December 31, 2017 2016 (unaudited) Total assets: Oncology Innovation Platform $ 97,562 $ 53,022 Global Supply Chain Platform 47,052 48,560 Commercial Platform 13,200 4,308 Total consolidated assets $ 157,814 $ 105,890
Summary of Revenue by Geographical Segment	Three Months Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 (unaudited) (unaudited) Total revenue: United States $ 2,227 $ 1,011 $ 2,940 $ 1,513 India 790 1,252 2,261 3,208 Austria 716 1,792 1,718 3,184 China 417 655 729 1,111 Taiwan - - 500 - Other foreign countries 445 483 1,028 806 Total consolidated revenue $ 4,595 $ 5,193 $ 9,176 $ 9,822
Summary of Property and Equipment by Geographical Segment	June 30, December 31, 2017 2016 (unaudited) Total property and equipment, net: United States $ 4,280 $ 2,177 China 4,041 3,633 Total consolidated property and equipment, net $ 8,321 $ 5,810
Summary of Customer Revenue and Accounts Receivable Concentration	Customer revenue and accounts receivable concentration amounted to the following for the identified periods. All customers relate to the Global Supply Chain Platform Segment. Three Months Ended June 30, Six Months Ended June 30, 2017 2016 2017 2016 (unaudited) (unaudited) Percentage of total revenue by customer: Customer A 17 % 24 % 22 % 33 % Customer B 15 % 31 % 18 % 31 % June 30, December 31, 2017 2016 (unaudited) Percentage of total accounts receivable by customer: Customer A 19 % 50 % Customer B 9 % 9 %

Commitments and Contingencies (

Commitments and Contingencies (Tables)	6 Months Ended
	Jun. 30, 2017
Commitments And Contingencies Disclosure [Abstract]
Schedule of Future Minimum Payments Under Non-Cancelable Leases	Future minimum payments under the non-cancelable leases consists of the following as of June 30, 2017 (in thousands): Year ending December 31: Minimum payments 2017 (remaining six months) $ 473 2018 1,298 2019 1,650 2020 1,659 2021 1,668 Thereafter 6,202 $ 12,950

Company and Nature of Business

Company and Nature of Business - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	Jun. 14, 2017	Jun. 30, 2017	Jun. 30, 2017	Dec. 31, 2016
Subsidiary Or Equity Method Investee [Line Items]
Accumulated deficit		$ 274,719	$ 274,719	$ 195,106
Common stock, shares issued		58,736,529	58,736,529	42,342,706
Convertible Bonds
Subsidiary Or Equity Method Investee [Line Items]
Convertible bonds, aggregate principal value	$ 68,000
Convertible bonds, carrying value	$ 55,800
Common Stock
Subsidiary Or Equity Method Investee [Line Items]
Aggregate cash proceeds net of underwriting discounts and commissions and offering costs		$ 64,200
Underwriting discounts and commissions		6,100	$ 6,100
Offering costs		$ 5,600	$ 5,600
Common Stock | Convertible Bonds
Subsidiary Or Equity Method Investee [Line Items]
Shares issued upon conversion	7,727,273
IPO
Subsidiary Or Equity Method Investee [Line Items]
Common stock, shares issued		6,900,000	6,900,000
Common stock share price		$ 11	$ 11
IPO | Common Stock
Subsidiary Or Equity Method Investee [Line Items]
Common stock share price		$ 11	$ 11
IPO | Common Stock | Convertible Bonds
Subsidiary Or Equity Method Investee [Line Items]
Shares issued upon conversion			7,727,273

Summary of Significant Accoun31

Summary of Significant Accounting Policies - Additional Information (Details) - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
Accounting Policies [Abstract]
Chargeback accrual	$ 1.5
Revenue recognition cash discount percentage	2.00%
Restricted net assets of the company's consolidated subsidiaries	$ 15.3	$ 15.7

Inventories, Net - Schedule of

Inventories, Net - Schedule of Inventories, Net (Detail) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Inventory Disclosure [Abstract]
Raw materials and purchased parts	$ 776	$ 977
Work in progress	3,792	2,727
Finished goods	4,692	536
Total inventories, net	$ 9,260	$ 4,240

Intangible Assets, Net - Summar

Intangible Assets, Net - Summary of Identifiable Intangible Asset, Net (Details) - USD ($) $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]
Finite-lived intangible asset, Accumulated Amortization		$ 1,224
Intangible asset, Effect of currency translation adjustment, Cost/Fair Value	$ (405)	(411)
Intangible asset, Effect of currency translation adjustment, Accumulated Amortization	(61)
Intangible asset, Effect of currency translation adjustment	(344)	(411)
Intangible assets Cost/Fair Value	11,186	10,082
Intangible assets Impairments	80	394
Intangible assets, net	9,242	8,464
Intangible asset, Accumulated Amortization	1,864
CDE In- Process Research and Development
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]
Indefinite-lived intangible asset, Cost/Fair Value	1,636	1,884
Indefinite-lived intangible asset, Accumulated Amortization	66
Indefinite-lived intangible asset, Impairments	80	248
Indefinite-lived intangible asset, Net	1,490	1,636
Licensing Agreements
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]
Finite-lived intangible asset, Cost/Fair Value	4,650	3,100
Finite-lived intangible asset, Accumulated Amortization	731	315
Finite-lived intangible asset, Net	3,919	2,785
Quad Pharma Customer List
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]
Finite-lived intangible asset, Cost/Fair Value		204
Finite-lived intangible asset, Accumulated Amortization		58
Finite-lived intangible asset, Impairments		146
Polymed Customer List
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]
Finite-lived intangible asset, Cost/Fair Value	1,593	1,593
Finite-lived intangible asset, Accumulated Amortization	545	414
Finite-lived intangible asset, Net	1,048	1,179
Polymed Technology
Schedule Of Finite And Indefinite Lived Intangible Assets [Line Items]
Finite-lived intangible asset, Cost/Fair Value	3,712	3,712
Finite-lived intangible asset, Accumulated Amortization	583	437
Finite-lived intangible asset, Net	$ 3,129	$ 3,275

Intangible Assets, Net - Additi

Intangible Assets, Net - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Finite Lived Intangible Assets [Line Items]
Intangible assets Impairments			$ 80		$ 394
Weighted-average useful life of intangible assets			7 years 10 months 14 days
Amortization expense of intangible assets	$ 400	$ 100	$ 800	$ 300
Research and Development Expenses
Finite Lived Intangible Assets [Line Items]
Intangible assets Impairments			100
Licensing Agreements | Hanmi Pharmaceuticals Co. Ltd.
Finite Lived Intangible Assets [Line Items]
Finite-lived intangible assets acquired					$ 400
Acquired finite-lived intangible assets, amortization period					12 years 9 months
Licensing Agreements | Gland Pharma Ltd
Finite Lived Intangible Assets [Line Items]
Finite-lived intangible assets acquired			$ 1,600		$ 2,700
Acquired finite-lived intangible assets, amortization period			5 years		5 years
Customer List | Athenex Pharma Solutions
Finite Lived Intangible Assets [Line Items]
Acquired finite-lived intangible assets, amortization period					7 years
Customer List | Polymed
Finite Lived Intangible Assets [Line Items]
Acquired finite-lived intangible assets, amortization period					6 years
Polymed Technology | Polymed
Finite Lived Intangible Assets [Line Items]
Acquired finite-lived intangible assets, amortization period					12 years

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair value assets, Level 1 to Level 2 transfers	$ 0	$ 0
Fair value assets, Level 2 to Level 1 transfers	0	0
Fair value liabilities, Level 1 to Level 2 transfers	0	0
Fair value liabilities, Level 2 to Level 1 transfers	0	0
Fair value assets, transfers into Level 3	0	0
Fair value assets, transfers out of Level 3	0	0
Fair value liabilities, transfers into Level 3	0	0
Fair value liabilities, transfers out of Level 3	$ 0	$ 0
Pharma Essentia | Taiwan OTC Exchange (TWO) | Level 1
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Number of shares owned by company	68,000

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Assets:
Total assets	$ 69,638	$ 15,490
Liabilities:
Total liabilities	1,632	8,795
Derivative Liability
Liabilities:
Total liabilities	1,632	8,795
Money Market Funds
Assets:
Total assets	22,169	6,522
Short-term Investments - Certificates of Deposit
Assets:
Total assets		8,628
Investment
Assets:
Total assets	330	340
Short-term Investments - Commercial Paper
Assets:
Total assets	19,945
Short-term Investments - Corporate Notes
Assets:
Total assets	10,017
Short-term investments - U.S. Government Bonds
Assets:
Total assets	17,177
Quoted Prices in Active Markets for Identical Assets (Level 1)
Assets:
Total assets	22,499	15,490
Quoted Prices in Active Markets for Identical Assets (Level 1) | Money Market Funds
Assets:
Total assets	22,169	6,522
Quoted Prices in Active Markets for Identical Assets (Level 1) | Short-term Investments - Certificates of Deposit
Assets:
Total assets		8,628
Quoted Prices in Active Markets for Identical Assets (Level 1) | Investment
Assets:
Total assets	330	340
Significant Other Observable Inputs (Level 2)
Assets:
Total assets	47,139
Significant Other Observable Inputs (Level 2) | Short-term Investments - Commercial Paper
Assets:
Total assets	19,945
Significant Other Observable Inputs (Level 2) | Short-term Investments - Corporate Notes
Assets:
Total assets	10,017
Significant Other Observable Inputs (Level 2) | Short-term investments - U.S. Government Bonds
Assets:
Total assets	17,177
Significant Unobservable Inputs (Level 3)
Liabilities:
Total liabilities	1,632	8,795
Significant Unobservable Inputs (Level 3) | Derivative Liability
Liabilities:
Total liabilities	$ 1,632	$ 8,795

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Changes in Fair Value of Company's Level 3 Financial Instruments (Details) - Derivative Liability $ in Thousands	6 Months Ended
	Jun. 30, 2017USD ($)
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Balance as of December 31, 2016	$ 8,795
Issuance of convertible bonds with embedded derivative	13,172
Change in fair value	8,863
Conversion of derivative liability to common stock	(29,198)
Balance as of June 30, 2017 (unaudited)	$ 1,632

Debt - Summary of Balances of D

Debt - Summary of Balances of Debt (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Jun. 14, 2017	Dec. 31, 2016
Debt Disclosure [Abstract]
Current portion of promissory notes to related parties	$ 1,064		$ 1,123
Current portion of mortgage	789		766
Current portion of capital lease obligation	43
Long-term portion of promissory notes to related parties			496
Long-term portion of capital lease obligation	191
Convertible bonds	5,042		14,498
Convertible bonds - related parties		$ 24,000	16,129
Derivative liability	1,632		8,795
Total	$ 8,761		$ 41,807

Debt - Additional Information (

Debt - Additional Information (Details) - USD ($) $ in Thousands	Jun. 14, 2017	Mar. 31, 2017	Jun. 30, 2017	Dec. 31, 2016	Jun. 30, 2016
Debt Instrument [Line Items]
Mortgage payment extended date			Jul. 30, 2017
Future minimum principal payment					$ 1,400
Future minimum principal payment					$ 500
Convertible bonds	$ 24,000			$ 16,129
Amount converted to common stock	$ 68,000		$ 85,000
Shares issued in conversion	7,727,273
License Agreement | Hanmi
Debt Instrument [Line Items]
Convertible bonds		$ 7,000
License upfront fees payable		$ 7,000
License Agreement | Hanmi | Minimum
Debt Instrument [Line Items]
Common stock discount rate		20.00%
License Agreement | Hanmi | Maximum
Debt Instrument [Line Items]
Common stock discount rate		22.00%
License Agreement | Hanmi | Bond
Debt Instrument [Line Items]
Promissory note maturity, ending date		Oct. 1, 2018
Interest rate		10.00%
Convertible Bonds
Debt Instrument [Line Items]
Promissory note maturity, ending date			Oct. 1, 2018
Convertible bonds issued by company			$ 75,000	$ 75,000
Convertible debt carrying value	$ 55,800
Promissory Note
Debt Instrument [Line Items]
Promissory note maturity term			36 months
Promissory note maturity, ending date			Jun. 1, 2018
Interest rate			6.00%

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Details)	3 Months Ended			6 Months Ended		12 Months Ended
	Jun. 30, 2017USD ($)shares	Mar. 31, 2017USD ($)RelatedParty	Jun. 30, 2016USD ($)	Jun. 30, 2017USD ($)shares	Jun. 30, 2016USD ($)	Dec. 31, 2016USD ($)shares	Dec. 31, 2015USD ($)$ / sharesshares	Dec. 31, 2014USD ($)$ / sharesshares	Jun. 14, 2017shares
Related Party Transaction [Line Items]
Stock-based compensation expense recognized	$ 6,676,000		$ 3,133,000	$ 8,820,000	$ 6,043,000
License fees and consulting revenue	98,000		71,000	696,000	166,000
Percentage of outstanding common stock holding		5.00%				5.00%
Convertible Bonds
Related Party Transaction [Line Items]
Amounts owed to related party	24,000,000	$ 4,000,000		24,000,000		$ 24,000,000
Amount purchased in convertible bonds by holders of outstanding common stock and entity affiliate		$ 2,000,000				$ 10,000,000
Number of related parties received convertible bonds | RelatedParty		2
Bonds converted into shares of common stock | shares									2,727,273
Restricted Stock
Related Party Transaction [Line Items]
Stock-based compensation expense recognized	540,000		1,120,000	$ 1,080,000	2,166,000
Executive Officer
Related Party Transaction [Line Items]
Shares of restricted stock sold on promissory notes | shares				2,520,000			1,200,000	1,320,000
Amount of promissory notes signed to fund stock purchases							$ 6,600,000	$ 6,000,000
Notes receivable least period				3 years
Notes Receivable Description				The Company has accounted for this related party transaction as a restricted stock offering, recognizing as an expense the value of the vested shares and the forgiveness of the notes over the three-year period, contingent on the continued employment of the executive.
Stock-based compensation expense recognized	$ 0		1,000,000	$ 0	2,100,000
Executive Officer | Restricted Stock
Related Party Transaction [Line Items]
Purchase price per share | $ / shares							$ 5.50	$ 4.55
Avalon BioMedical
Related Party Transaction [Line Items]
Common stock shares held by related parties | shares	678,880			678,880		678,880
Percentage of common stock issued shares				1.20%		1.70%
Avalon BioMedical | CDE | Research and Development Facility
Related Party Transaction [Line Items]
Percentage of rent payment				30.00%
Pharma Essentia
Related Party Transaction [Line Items]
Licenses revenue	$ 0		0	$ 500,000	0
Taisheng
Related Party Transaction [Line Items]
Purchases of pharmaceutical ingredients from related party	0		0	0	200,000
Amounts owed to related party	0			0		$ 0
ZenRx
Related Party Transaction [Line Items]
Amounts owed to related party	100,000			100,000
License fees and consulting revenue				0
ZenRx | Maximum
Related Party Transaction [Line Items]
Amounts owed to related party						$ 100,000
ZenRx | Clinical Development Services
Related Party Transaction [Line Items]
Payments to related party for services received	100,000			200,000
ZenRx | Clinical Development Services | Maximum
Related Party Transaction [Line Items]
Payments to related party for services received			100,000		100,000
RSJ Consulting LLC
Related Party Transaction [Line Items]
Consulting services incurred				$ 100,000	$ 200,000
RSJ Consulting LLC | Maximum
Related Party Transaction [Line Items]
Consulting services incurred	$ 100,000		$ 100,000

Stockholders Equity - Additiona

Stockholders Equity - Additional Information (Details) $ / shares in Units, $ in Thousands	Jun. 14, 2017USD ($)shares	Jun. 30, 2017USD ($)Plan$ / sharesshares	Jun. 30, 2016$ / sharesshares	Dec. 31, 2016USD ($)$ / sharesshares
Class Of Stock [Line Items]
Common stock, shares authorized		250,000,000	250,000,000	250,000,000
Common stock, par value | $ / shares		$ 0.001	$ 0.001	$ 0.001
Common stock, voting rights		one vote per share
Purchase of shares of common stock		16,000
Costs incurred in raising equity | $	$ 11,700	$ 9,044
Number of stock option plans | Plan		3
2013, 2007 and 2004 Plans | Maximum
Class Of Stock [Line Items]
Common stock options authorized grant		11,800,000
2017 Plans
Class Of Stock [Line Items]
Common stock reserved for future issuance		5,200,000
Shares issued		0
Common Stock
Class Of Stock [Line Items]
Sale of common stock, shares		6,900,000	1,133,332
Convertible Bonds | Common Stock
Class Of Stock [Line Items]
Shares issued upon conversion	7,727,273
IPO
Class Of Stock [Line Items]
Sale of common stock, shares		6,900,000
Common stock share price | $ / shares		$ 11
Shares from the exercise of warrants and options		406,386
Vesting of restricted stock units and grant of shares		791,982
Cumulative increase to equity shares value | $		$ 164,700
Costs incurred in raising equity | $		$ 11,700
IPO | 2017 Plans
Class Of Stock [Line Items]
Common stock reserved for future issuance		1,000,000
IPO | Other Long-term Assets [Member]
Class Of Stock [Line Items]
Deferred costs | $				$ 1,800
IPO | Licensing Agreements
Class Of Stock [Line Items]
Sale of common stock, shares		568,182
IPO | Common Stock
Class Of Stock [Line Items]
Common stock share price | $ / shares		$ 11
IPO | Convertible Bonds | Common Stock
Class Of Stock [Line Items]
Shares issued upon conversion		7,727,273

Stock Based Compensation - Addi

Stock Based Compensation - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options granted contractual term			10 years
Stock-based compensation expense	$ 6,676,000	$ 3,133,000	$ 8,820,000	$ 6,043,000
Unrecognized cost related to non-vested stock options expected to be recognized	$ 17,900,000		$ 17,900,000		$ 11,000,000
Unrecognized cost related to non-vested stock options, weighted-average period of recognition			1 year 10 months 24 days		1 year 7 months 6 days
Intrinsic value of options exercised			$ 400,000
Warrants outstanding	0		0		344,000
Common Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense	$ 4,400,000	1,000,000	$ 4,400,000	2,100,000
Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense	$ 1,736,000	$ 2,013,000	$ 3,340,000	3,877,000
Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options granted, vesting period			2 years
Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock options granted, vesting period			4 years
Intrinsic value of options exercised				$ 100,000

Stock Based Compensation - Sche

Stock Based Compensation - Schedule of Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2017	Dec. 31, 2016
Stock Options
Stock Options, Outstanding Beginning Balance	9,280,689
Stock Options, Granted	1,626,532
Stock Options, Exercised	(72,320)
Stock Options, Forfeited	(70,042)
Stock Options, Expired	(9,273)
Stock Options, Outstanding Ending Balance	10,755,586	9,280,689
Stock Options, Vested and exercisable at June 30, 2017	7,547,480
Weighted Average Exercise Price
Weighted Average Exercise Price, Outstanding Beginning Balance	$ 6.26
Weighted Average Exercise Price, Granted	11
Weighted Average Exercise Price, Exercised	6.06
Weighted Average Exercise Price, Forfeited	9.29
Weighted Average Exercise Price, Expired	3.54
Weighted Average Exercise Price, Outstanding Ending Balance	6.96	$ 6.26
Weighted Average Exercise Price, Vested and exercisable at June 30, 2017	$ 5.85
Weighted Average Remaining Contractual Term
Weighted Average Remaining Contractual Term, Outstanding	7 years 2 months 30 days	7 years 3 months 4 days
Weighted Average Remaining Contractual Term, Vested and exercisable at June 30, 2017	6 years 5 months 16 days
Aggregate Intrinsic Value
Aggregate Intrinsic Value, Outstanding	$ 99,376	$ 43,994
Aggregate Intrinsic Value, Vested and exercisable at June 30, 2017	$ 78,092

Stock Based Compensation - Sc44

Stock Based Compensation - Schedule of Weighted Average Assumptions Used as Inputs to Black-Scholes Model (Details) - $ / shares	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Weighted average grant date fair value	$ 6.49	$ 5.29
Expected stock price volatility	66.00%	65.00%
Risk-free interest rate	1.74%	1.20%
Expected life of options (in years)	6 years 2 months 12 days	6 years

Stock Based Compensation - Sc45

Stock Based Compensation - Schedule of Restricted Stock Activity (Details)	6 Months Ended
	Jun. 30, 2017$ / sharesshares
Shares of Restricted Stock
Shares of Restricted Stock, Nonvested Beginning Balance | shares	661,982
Shares of Restricted Stock, Vested | shares	(391,982)
Shares of Restricted Stock, Nonvested Ending Balance | shares	270,000
Weighted Average Fair Value
Weighted Average Fair Value, Nonvested Beginning Balance	$ 9
Weighted Average Fair Value, Nonvested Granted	9
Weighted Average Fair Value, Nonvested Vested	9
Weighted Average Fair Value, Nonvested Ending Balance	$ 9

Stock Based Compensation - Sc46

Stock Based Compensation - Schedule of Stock-Based Compensation Cost (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense recognized	$ 6,676	$ 3,133	$ 8,820	$ 6,043
Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense recognized	1,736	2,013	3,340	3,877
Vesting of Restricted Stock Grants
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense recognized	540	1,120	1,080	2,166
Stock Awarded to Directors and Officers
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense recognized	4,400		4,400
Cost of Product Sales
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense recognized	26		48
Research and Development Expenses
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense recognized	447	1,610	908	3,165
Selling, General, and Administrative
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock-based compensation expense recognized	$ 6,203	$ 1,523	$ 7,864	$ 2,878

Net Loss per Share Attributab47

Net Loss per Share Attributable to Athenex, Inc. Common Stockholders - Schedule Outstanding Shares of Common Stock Equivalents Excluded from the Calculation of Diluted Net Loss Per Share (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total potential dilutive shares	10,415,740	12,190,387	10,378,581	12,175,439
Stock Options and Other Common Stock Equivalents [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total potential dilutive shares	9,819,089	11,136,500	9,749,264	11,016,552
Unvested Restricted Shares [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Total potential dilutive shares	596,651	1,053,887	629,317	1,158,887

Business Segment, Geographic,48

Business Segment, Geographic, and Concentration Risk Information - Additional Information (Details)	6 Months Ended
	Jun. 30, 2017segment
Segment Reporting [Abstract]
Number of operating segments	3
Number of reportable segments	2

Business Segment, Geographic,49

Business Segment, Geographic, and Concentration Risk Information - Summary of Segment Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Net (loss) income attributable to Athenex, Inc.:
Total consolidated net loss attributable to Athenex, Inc.	$ (38,625)	$ (12,421)	$ (79,613)	$ (23,039)
Operating Segments | Oncology Innovation Platform
Net (loss) income attributable to Athenex, Inc.:
Total consolidated net loss attributable to Athenex, Inc.	(33,018)	(12,037)	(61,277)	(22,452)
Operating Segments | Global Supply Chain Platform
Net (loss) income attributable to Athenex, Inc.:
Total consolidated net loss attributable to Athenex, Inc.	(1,981)	428	(3,129)	225
Operating Segments | Commercial Platform
Net (loss) income attributable to Athenex, Inc.:
Total consolidated net loss attributable to Athenex, Inc.	$ (3,626)	$ (812)	$ (15,207)	$ (812)

Business Segment, Geographic,50

Business Segment, Geographic, and Concentration Risk Information - Summary of Revenue by Segments (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Total revenue:
Total consolidated revenue	$ 4,595	$ 5,193	$ 9,176	$ 9,822
Operating Segments
Total revenue:
Total consolidated revenue	6,599	6,653	13,705	12,151
Operating Segments | Oncology Innovation Platform
Total revenue:
Total consolidated revenue	270	404	1,003	546
Operating Segments | Global Supply Chain Platform
Total revenue:
Total consolidated revenue	4,509	6,249	10,806	11,605
Operating Segments | Commercial Platform
Total revenue:
Total consolidated revenue	1,820	0	1,896	0
Intersegment Eliminations
Total revenue:
Total consolidated revenue	$ (2,004)	$ (1,460)	$ (4,529)	$ (2,329)

Business Segment, Geographic,51

Business Segment, Geographic, and Concentration Risk Information - Summary of Revenue by Product Group (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Total revenue by product group:
Total consolidated revenue	$ 4,595	$ 5,193	$ 9,176	$ 9,822
API Sales
Total revenue by product group:
Total consolidated revenue	2,024	3,726	5,023	7,688
Medical Device Sales
Total revenue by product group:
Total consolidated revenue	232	519	567	876
Contract Manufacturing Revenue
Total revenue by product group:
Total consolidated revenue	247	544	684	712
Commercial Product Sales
Total revenue by product group:
Total consolidated revenue	1,913	31	2,042	32
License Fees and Consulting Revenue
Total revenue by product group:
Total consolidated revenue	98	71	696	166
Grant Revenue
Total revenue by product group:
Total consolidated revenue	$ 81	$ 302	$ 164	$ 348

Business Segment, Geographic,52

Business Segment, Geographic, and Concentration Risk Information - Summary of Depreciation, Amortization and Assets by Segment (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Total depreciation and amortization:
Total consolidated depreciation and amortization	$ 848	$ 335	$ 1,664	$ 752
Total assets:
Total consolidated assets	157,814		157,814		$ 105,890
Operating Segments | Oncology Innovation Platform
Total depreciation and amortization:
Total consolidated depreciation and amortization	120	51	212	98
Total assets:
Total consolidated assets	97,562		97,562		53,022
Operating Segments | Global Supply Chain Platform
Total depreciation and amortization:
Total consolidated depreciation and amortization	495	284	1,021	654
Total assets:
Total consolidated assets	47,052		47,052		48,560
Operating Segments | Commercial Platform
Total depreciation and amortization:
Total consolidated depreciation and amortization	233	$ 0	431	$ 0
Total assets:
Total consolidated assets	$ 13,200		$ 13,200		$ 4,308

Business Segment, Geographic,53

Business Segment, Geographic, and Concentration Risk Information - Summary of Revenue by Geographical Segment (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016
Total revenue:
Total consolidated revenue	$ 4,595	$ 5,193	$ 9,176	$ 9,822
United States
Total revenue:
Total consolidated revenue	2,227	1,011	2,940	1,513
India
Total revenue:
Total consolidated revenue	790	1,252	2,261	3,208
Austria
Total revenue:
Total consolidated revenue	716	1,792	1,718	3,184
China
Total revenue:
Total consolidated revenue	417	655	729	1,111
Taiwan
Total revenue:
Total consolidated revenue	0	0	500	0
Other Foreign Countries
Total revenue:
Total consolidated revenue	$ 445	$ 483	$ 1,028	$ 806

Business Segment, Geographic,54

Business Segment, Geographic, and Concentration Risk Information - Summary of Property and Equipment by Geographical Segment (Details) - USD ($) $ in Thousands	Jun. 30, 2017	Dec. 31, 2016
Total property and equipment, net:
Total consolidated property and equipment, net	$ 8,321	$ 5,810
United States
Total property and equipment, net:
Total consolidated property and equipment, net	4,280	2,177
China
Total property and equipment, net:
Total consolidated property and equipment, net	$ 4,041	$ 3,633

Business Segment, Geographic,55

Business Segment, Geographic, and Concentration Risk Information - Summary of Customer Revenue and Accounts Receivable Concentration (Details) - Customer Concentration Risk	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Customer Revenue | Customer A
Concentration Risk [Line Items]
Concentration risk, percentage	17.00%	24.00%	22.00%	33.00%
Customer Revenue | Customer B
Concentration Risk [Line Items]
Concentration risk, percentage	15.00%	31.00%	18.00%	31.00%
Accounts Receivable | Customer A
Concentration Risk [Line Items]
Concentration risk, percentage			19.00%		50.00%
Accounts Receivable | Customer B
Concentration Risk [Line Items]
Concentration risk, percentage			9.00%		9.00%

Commitments and Contingencies -

Commitments and Contingencies - Schedule of Future Minimum Payments Under Non-Cancelable Leases (Details) $ in Thousands	Jun. 30, 2017USD ($)
Commitments And Contingencies Disclosure [Abstract]
2017 (remaining six months)	$ 473
2,018	1,298
2,019	1,650
2,020	1,659
2,021	1,668
Thereafter	6,202
Future minimum payments under non-cancelable leases	$ 12,950